文献速递肝病

治疗期间转氨酶水平预测1型自身免疫性肝炎患者长期生存

Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-05-20

该多中心队列纳入301例1型自身免疫性肝炎患者,中位随访99个月,采用标志点分析发现治疗12个月时AST升高与更差的长期无移植生存独立相关,而IgG无此关联,提示转氨酶正常化应作为治疗目标。

核心结论

  • 治疗期间转氨酶水平低与自身免疫性肝炎患者更好的长期生存相关,转氨酶正常化应作为治疗目标。

研究设计与样本

  • 多中心队列研究,纳入301例自身免疫性肝炎患者,中位随访99个月(范围7-438个月),在诊断时及治疗开始后6、12、24、36个月收集ALT、AST和IgG,采用Kaplan-Meier生存分析和Cox回归,并在各时间点进行标志点分析。

主要发现

  • 随访期间15例患者需肝移植,33例死亡。

临床怎么用

  • 在自身免疫性肝炎治疗随访中,应关注转氨酶(尤其是AST)的动态变化,以转氨酶正常化作为治疗目标以改善长期生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biochemical remission, important treatment goal in autoimmune hepatitis (AIH), has been associated with better long-term survival. The aim of this study was to determine the independent prognostic value of aminotransferases and immunoglobulin G (IgG) during treatment on long-term transplant-free survival in AIH. METHODS: In a multicenter cohort alanine aminotransferase, aspartate aminotransferase (AST), and IgG were collected at diagnosis and 6, 12, 24, and 36 months after start of therapy and related to long-term outcome using Kaplan-Meier survival and Cox regression analysis with landmark analysis at these time points, excluding patients with follow-up ending before each landmark. RESULTS: A total of 301 AIH patients with a median follow-up of 99 (range, 7-438) months were included. During follow-up, 15 patients required liver transplantation and 33 patients died. Higher AST at 12 months was associated with worse survival (hazard ratio [HR], 1.86; P < .001), while IgG was not associated with survival (HR, 1.30; P = .53). In multivariate analysis AST at 12 months (HR, 2.13; P < .001) was predictive for survival independent of age, AST at diagnosis and cirrhosis. Multivariate analysis for AST yielded similar results at 6 months (HR, 2.61; P = .001), 24 months (HR, 2.93; P = .003), and 36 months (HR, 3.03; P = .010). There was a trend toward a worse survival in patients with mildly elevated aminotransferases (1-1.5× upper limit of normal) compared with patients with normal aminotransferases (P = .097). CONCLUSIONS: Low aminotransferases during treatment are associated with a better long-term survival in autoimmune hepatitis. IgG was not associated with survival in first 12 months of treatment. Normalization of aminotransferases should be the treatment goal for autoimmune hepatitis to improve long-term survival.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Biewenga M, Verhelst X, Baven-Pronk M, et al. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. Clin Gastroenterol Hepatol. 2021. PMID: 34022454. doi:10.1016/j.cgh.2021.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。